Concurrent treatment by fetal precursor cell transplantation and pharmaceutical drugs of chemical nature
Toxicity of chemical drugs for the entire body, or for certain organ systems, is investigated during the drug approval process by regulatory authorities, but such routine procedures do not include an investigation of the effect of individual drugs of chemical nature on the transplanted fetal precursor cells.
Under such circumstances a warning to minimize the intake of drugs of chemical nature during 24 – 48 hours prior to fetal precursor cell transplantation and for 72 hours thereafter is logical.
The intake of essential drugs must continue, but all others, often prescribed by various physicians, that did not check the patient’s ‘brown bag’, can usually be stopped for a few days without any harm, if not permanently.
The toxicity of drugs of chemical nature for fetal precursor cell transplants is not the only matter of concern to cell transplantologists. Sometimes the interaction between cell transplants and essential drugs is of different nature, as for example in type 1 diabetic that continues to take insulin while undergoing fetal precursor cell transplantation
As with other diseases where there is a standard treatment, in the treatment of diabetic complications fetal precursor cell transplantation has to be carried out concurrently with the standard treatment of IDDM that is not altered.
As the transplanted cells do not begin their functioning, or their stimulation of patient’s own cells does not start, until one to two months later, it is impossible to stop the ongoing insulinotherapy, even though there is most likely a competitive inhibition of the insulin production by the implanted ß-cells of the Langerhans islands, or the ‘re-awakened’ ß-cells of the patient, and by the exogenous insulin. At the same time insulin, being a natural substance, is not toxic to the transplanted cells, and thus insulinotherapy can continue without any harm to the transplanted cells.
Logically there is hardly any additive effect between fetal precursor cell transplantation and insulinotherapy, on the contrary there is some degree of competitive inhibition, but this is an unavoidable fact, that has to be taken under scientific and statistical consideration in the evaluation of results.
The concomitant insulinotherapy does not influence the level of serum C-peptide and/or the clinical course of already developed diabetic complications, so that the measured changes of the clinical parameters after the fetal precursor cell transplantation can be safely ascribed to the beneficial effect of this treatment.